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I. ABSENCE OF CORRELATION WITH CYTOTOXIC EFFECTOR CELLS1
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Cell-mediated immunity against minor histocompati-
bility (mH) antigens is assumed to contribute to the
development of graft-vs.-host disease in recipients of
HLA-identical bone marrow grafts. To investigate the
role of antihost-specific cytotoxic effector cells, we ana-
lyzed patients' Τ cell cultures after transplantation, in
a chromium release assay using Τ lymphoblasts from
patients and donors as target cells. Sixteen patients were
studiedbetween 1 and 25 months after grafting. Specific
antihost cytotoxic Τ cell activity was detected in 4 of 5
patients with acute GVHD and in 5 of 5 patients with
chronic GVHD, but also in 5 of 6 patients without any
clinical signs of GVHD. Generally, the antihost Tc cell
activity appeared within the first 3 months, increased
to a maximum between 3 and 6 months, and gradually
disappeared thereafter. This time effect was significant
(P = 0.002). There was a suggestive trend in patients
with chronic GVHD toward developing higher and more
persistent levels of antihost Tc cell activity than in those
without GVHD. Yet, these results can no longer support
our earlier finding that the generation of antihost Tc
cells is associated with the development of GVHD, since
antihost Tc cells could be generally detected whether or
not GVHD occurred. Our findings do not a priori exclude
an effector cell role for Tc cells in GVHD but strongly
indicate that other risk factors must be involved as well.
Allogeneic bone marrow transplantation is increasingly used
to eure a variety of hematological disorders, such as aplastic
anemia and leukemia (1). However, transplantation reactions
such as graft-vs.-host disease and graft rejeetion are two major
limits to the success of this treatment (2-4). In HLA-identical
transplantation, the degree of mismatching for so-called minor
histocompatibility (mH)* antigens between donor and host is
thought to influence the likelihood of GVHD and graft rejeetion
(5). Unfortunately, these Τ cell-med'ated host-graft interac-
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tions seem to be related in a mutually exclusive way (6), such
that attempts to prevent GVHD likely increase the ineidence
of graft rejeetion and vice versa (7, 8). Α better understanding
of the cellular mechanisms underlying GVHD and graft rejee-
tion is presently needed to manage this dilemma.
The involvement of antihost-specific cytotoxic Τ cells as
effector cells in GVHD induced to mH antigens was first
suggested by experimental studies in mice. Anti-recipient
strain Tc cells could be demonstrated in spleens of mice
undergoing GVHD (9). Likewise, antihost cytotoxic effector
cell populations could be isolated from patients achieving
GVHD after HLA-identical BMT (10,11). Recently, we showed
that the presence of mH antigen-speeifie Tc cells shortly after
grafting was associated with the development of chronic GVHD
(5, 12). Further, it was demonstrated by Tsoi et al. (13, 14)
that cytotoxicity of patients' post-BMT lymphocytes against
host fibroblasts in a cellular Inhibition assay tended to correlate
with the oecurrence of acute GVHD. Interestingly, these latter
studies suggested that the time of onset of GVHD was crucial
for the detection of the antihost cytotoxicity, which emerged
only between one and two months after the development of
GVHD. To gain insight into this time effect and to extend our
earlier observations, we here investigated the antihost-specific
Tc cell reactivities in sixteen patients sequentially after trans-
plantation. The results are consistent with our previous studies
in that strong, host-directed Tc cells emerge in all patients with
chronic GVHD, but differ with regard to the ineidence in
patients without GVHD and with acute GVHD. Our findings
may have a bearing on current coneepts of the biological role
of antihost-specific Tc cells in BMT.
MATERIALS AND METHODS
Patients. Sixteen patients (6 male, 10 female) reeeived bone marrow
from their HLA-A, -B, -Cw, -DR-identical, MLC-nonreactive sibling
donors. As a conditioning regimen for transplantation, 15 patients with
leukemia reeeived cyclophosphamide (60 mg/kg/day X2) and total-
body Irradiation (8 Gy), 1 patient with aplastic anemia reeeived cyclo-
phosphamide (50 mg/kg/day X4) and total-lymphoid Irradiation (2 Gy/
day xlO). To prevent acute GVHD, 11 patients were given methotrex-
ate and 5 patients were given cyclosporine A. All patients lived at least
100 days after grafting and thus were at risk for acute and chronic
GVHD. Acute GVHD was diagnosed in 10 patients, 5 of whom later
developed chronic GVHD. Clinical information on the patients is
summanzed in Table 1. The Standard protoeol for MTX was 15 mg/
m
2
 i.v. on day 1, 10 mg/m2 on days 3, 6, 9, and 11 after transplantation;
and thereafter weekly for the first 100 days. CsA was given as a
continuous i.v. infusion, 3 mg/kg/day, started on day - 1 , followed by
oral administration (9 mg/kg/day). The dose was adjusted aecording
to the clinical course, renal funetion, and plasma concentration of CsA
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TABLE 1. Clinical Information concerning the patients
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1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
upc°
6500
6545
6223
6217
6346
6825
6284
7035
7431
6067
7288
6072
6966
7448
7037
7384
Age
33
31
42
20
24
17
21
36
38
15
38
26
32
38
40
39
Sex
Mb
Μ
F
F
Μ
F
Μ
F
F
Μ
F
F
F
F
Μ
F
Patients
Sex
mis-
match
No
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No
Yes
Yes
Yes
No
No
No
Diagnosis
ANLC V
A L L 2 "
A N L 1 "
A N L 1 "
ANL1°
A L L 1 "
SAA
A N L 1 "
A N L 1 *
A N L 1 "
ANL1°
ALL2"
A N L l "
ANLl·
A N L l "
A N L l *
Survival
after
grafting
>760 e
538
>760
609
>760
>760
143
>760
>760
>760
175
>760
394
267
137
>760
cause of
death
Alive
Leukemia
Alive
Leukemia
Alive
Alive
Transplant
Alive
Alive
Alive
Transplant
Alive
Transplant
Transplant
Transplant
Alive
Graft-versua-ht
Prophylaxis
M T X '
MTX
MTX
MTX
MTX
MTX
MTX
MTX
CsA
MTX
CsA
MTX
MTX
CsA
CsA
CsA
Acute
GVHD
0*
0
0
0
0
0
II
II
I
II
II
II
II
III-IV
III-IV
I
)st diseaee
—
—
—
—
—
34'
54
12
33
14
18
28
12
11
17
Chronic
GVHD
O6
0
0
0
0
0
0
0
0
0
0
1
2
2
2
1
renuü ui
in vitro
testing
40-187'
36-336
43-677
139-382
43-711
124-697
40-97
97-773
29-729
50-773
29-158
25-773
33-382
27-180
22-137
29-572
' Unique patient code.
6
 M: male; F: female.
' ANL: acute nonlymphoblastic leukemia; ALL: acute lymphoblastic leukemia; SAA: severe aplastic leukemia.
d
 1°, 2°: first, second remission.
' Days after transplantation.
' MTX: methotrexate; CsA: cyclosporine.
' Acute GvHD grade.
* Chronic GVHD grade: 0 = none; 1 = limited; 2 = extensive.
' Day of onset of acute GVHD.
(600-1000 fig/ml). Generally, the oral dose was slowly tapered over a
period of months with the aim of discontinuing it at 3-4 months after
transplantation. As therapy for GVHÜ, patients received prednisone
(1-2 mg/kg/day for 10-14 days, then tapered) or high-dose methyl-
prednisolone (20 mg/kg/12 hr for 2 days, then tapered). Patients who
developed chronic GVHD were treated with prednisone (1 mg/kg/day)
and/or azathioprine (2 mg/kg/day).
Blood samples. Heparinized blood samples were collected from recip-
lents before and periodically after transplantation, from the sibling
bone marrow donors, and from HLA-typed unrelated individuals. The
patients were scheduled to be tested at days 30, 60, 90, 180, 360, and
720—missing intervals were caused by early lymphopenia or by the
death of patients (see Table 1). Peripheral blood leukocytes were
isolatedby ficoll-isopaque density gradient centrifugation, washed, and
resuspended in RPMI 1640-dimethylsulfoxide (final concentration
10%) for cryopreservation in liquid nitrogen.
Tissue culture medium. All Τ cell cultures were performed in RPMI
1640 supplemented with antibiotics (gentamycin) and 15% human
serum.
Generation of host- and allo-HLA-specific Τ cell lines. Τ cell lines in
the GVH direction were generated as follows; 4X106 responder cells,
either PBL from patients (n = 16) obtained sequentially after trans-
plantation or PBL from bone marrow donors (n = 12), as unprimed
controls were stimulated with 4X10" 20 Gy irradiated patients' pretran-
splantation PBL as host-specific antigen-presenting cells. At day 6,
responder Τ cells were specifically restimulated and further propagated
as deseribed elsewhere (15). To study HLA-specific Τ cell alloreactiv-
ities, the patients' blood samples up to 6 (or 9, see the accompanying
article) months after BMT were, in a separate analysis, also sensitized
agamst irradiated stimulator cells from an unrelated HLA-mismatched
donor. To limit the experimental Variation, for each patient the long
!"m antihost and anti-HLA -reactive analyses (Table 2) were carried
'<ut simultaneously.
Phenotype analysis. Patients post-BMT Τ cell lines were stained for
f
 D3, CD4, and CD8 expression by a Standard double immunofluores-
TABLE 2. Flow chart of the sensitization and the functional analysis
of host antigen and HLA antigen specific Τ cell lines
In vitro sensitization phase
Alloantigen
mH
HLA
Responder
Recipient'
Donor
Recipient
Donor
Stimulatorc
Host*
Host
Unrelated
Unrelated
Effector phase
CML"/PLT*
(targetVstimulator')
Host/donor
Host/donor
Unrelated/donor
Unrelated/donor
° Functional assay in this study.
b
 Functional assay in the accompanying article (7).
' On days 0 and 6 (PBL).
d
 PHA-stimulated lymphoblasts.
«PBL.
'At different times after BMT.
8
 Derived from recipients before transplantation.
cence technique, using PE- and FITC-conjugated Leu4 (CD3), Leu3a
(CD4), and Leu2a (CD8) monoclonal antibodies, and were assayed on
a fluorescence activated cell sorter. All samples tested (n = 52) were
CD3+ (94±8%) and showed an equal mean distribution of CD4+ cells
(51+27%) and CD8+ cells (46±28%, data not shown).
Cell-mediated lympholysis asssay. Tc cell activity was determined
using 3-4-weeks-old Τ cell lines from patients and donors as effector
cells in a Standard 6 1Cr release assay (16). Target cells were Τ lympho-
blasts derived from the original stimulator—i.e., from the host before
transplantation to measure the host-specific reactivities, or from the
HLA-mismatched unrelated donor to measure the HLA antigen-di-
rected reactivities. Τ lymphoblasts from the bone marrow donor were
used as an autologous control. Briefly, 5xlO 3 51Cr-labeled Τ lympho-
blasts, generated by treatment of PBL with 1% PHA mitogen (Difco)
for 3 days and expanded on 11-2, were incubated at 37°C for 4 hr
together with 2X105 effector cells (E:T = 40:1). Then the supernatants
were harvested for counting in a gamma counter (Packard Instru-
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ments). Perrentages of specific 6 lCr release were calculated according
to the following formula: ER-SR/MR-SR x 100%, in which experi-
mental, spontaneous, and maximal release (ER, SR, and MR) were,
respectively, the 61Cr release by target cells measured in the presence
of effector cells (ER), in culture medium alone (SR), and in culture
medium with the detergent zaponine (MR).
Statistical methods. Α multivariate analysis of variance model (Man-
ova) (17) was applied, containing group-, time-, and group-by-time
interacting terms, to determine the levels of significance of the differ-
ences in antihost Tc cell activity between different intervals after
transplantation and between different patient groups achieving no,
acute, or acute followed by chronic GVHD.
RESULTS
Evidence that posttransplantation Tc cell activities are specif-
ically directed against the host. Τ cell lines were induced from
the PBL of 16 patients, obtained at different times between 1
and 25 months after HLA-identical BMT, which were sensi-
tized with patients' own pretransplantation PBL. Thirteen
patients were studied 3 or more times after grafting, whereas 3
patients were only studied twice. We analyzed a total of 60 Τ
cell cultures for the presence of Tc cell reactivities against host
and donor target cells in a 51Cr release assays (Table 2). As is
shown in Table 3, significant cytotoxicity (i.e., more than 20%
of lysis) against host target cells was detected in 39 of the 60
host-sensitized cultures, whereas no cultures showed Tc cell
activity against the donor. Thus, all activities detected were
host-specific.
Absence of in vitro generation of antihost-specific Tc cell
activities from unprimed donors. To investigate whether the
host-specific cytotoxicity could possibly have been introduced
by in vitro manipulation, cytotoxic assays were also performed
with Τ cell lines derived from 12 marrow donors (Table 2). The
Tc cell activities against host as well as donor targets were
negligible in 11 of 12 donor Τ cell lires (Table 3). One female
donor, who was sensitized in vivo by pregnancies, showed Tc
cell reactivity specifically against host target cells. Hence, an-
tihost Tc cell reactivity could not usually be generated in vitro.
Kinetics of the antihost specific Tc cell activities after trans-
plantation. The 39 cell cultures with antihost-specific Tc cell
activity (Table 3) originated from 14 of 16 patients (Fig. 1).
Two patients (2 and 8) remained negative for at least one year
and two years, respectively. The other 14 patients showed
considerable Variation with respect to the magnitude and the
kinetics of their antihost To cell activities. In some patients
more than 20% of antihost lysis was found in all samples
(1,7,11,12,13, and 16) while in other patients cytotoxicity was
only demonstrated in some samples (3,4,5, 6,9,10,14, and 15).
Of the 14 patients who achieved antihost Tc cells, 12 were
evaluated during the first 3 months (1,3,5,7,9-16). In 10 of these
TABLE 3. Detection of host-specific Tc cell activity in patients' post-
BMT and donots' Τ cell lines
Anti-host cytotoxicity Yes
No
Anti-donor
cytotoxicity
Yes
0/60°
0/12*
0/60
0/12
No
39/60
1/12
21/60
11/12
• Patients' post-BMT Τ cell lines (ntot*' = 60).
b
 Donor-derived Τ cell lines (n™"1 = 12).
12 patients the Tc cell activity already appeared within this
period (1,3,6,7,10,11,12,13,14, and 16). Thereafter, the activity
tended to increase to a maximum level between 3 and 6 months.
Variance analysis showed that the average antihost Tc cell
activity in the latter interval (61±7%) was significantly higher
than the averages found between 0 and 1.5 months (31±6%, Ρ
= 0.004) and between 1.5 and 3 months (39±7%, Ρ = 0.039).
Although Tc cell activities persisting for at least two years
could be found in a few patients (e.g. 12 and 16), Tc cell
activities gradually decreased after 3-6 months (e.g., in patients
3,4,5,9,10, and 13). This trend was also significant. The average
antihost Tc cell activity between 9 and 12 months (49+7%)
was significantly lower than between 3 and 6 months (61±7%,
Ρ = 0.005), while the average antihost Tc cell activity between
12 and 25 months (24±7%) was significantly lower than be-
tween 3 and 6 months (P = 0.001) and 6 and 9 months (49±
7%, Ρ = 0.012).
Early regeneration of Tc cell activity against HLA alloantigens.
To test the possibility that the failure to detect antihost Tc
cells shortly after grafting as observed in several patients might
reflect a general Tc cell impairment (as a result of incomplete
Τ cell reconstitution or immunosuppression) rather than a
specific nonresponsiveness to host antigens, we analyzed the
capacity of the 16 patients' lymphocytes up to 6 months to
mount an in vitro Tc cell response to HLA alloantigens (Table
2). All lymphocyte samples that were sensitized against HLA
alloantigens (n = 29) showed strong Tc cell activity against the
original stimulator cells (84+20% lysis) but not against the
autologous donor cells (1+3% lysis, data not shown). Thus, the
Tc cell responses against HLA alloantigens were functionally
restored in all patient samples studied.
Absence of corretotion between antihost-specific Tc cell activ-
ities and the development of acute or chronic GVHD. The
antihost Tc cell activities observed in patients without GVHD
(Fig. 1A) were compared with the results obtained in patients
who developed acute GVHD (Fig. 1B) or acute and subse-
quently chronic GVHD (Fig. IC). Variance analysis showed no
statistically significant differences between groups. All patients
who achieved chronic GVHD (n = 5) generated antihost Tc
cells; in 3 of these (12, 13, and 16) extremely high cytotoxicity
levels were observed shortly after grafting, while 4 of 5 patients
with acute GVHD, and 5 of 6 patients without GVHD also
developed Tc cells. The statistical analysis showed that the
average antihost Tc cell activity in patients with chronic GVHD
(51+9%) was higher than in patients without GVHD (28±9%)
or with acute GVHD (38±10%)—however, these differences
were not significant.
DISCUSSION
In our earlier studies we found an association between the
presence of circulating antihost-specific Tc cells at about 40
days after BMT and the development of chronic GVHD (5,
12). Currently, with longer-term studies for antihost Tc cells,
we observed that patients could be unresponsive until or even
beyond day 40, but still could develop an antihost Tc cell
response in a later phase. However, the main finding of this
study, which does not support our previous conclusion, is that
antihost Tc cells seem to occur frequently, and not only in
patients with chronic GVHD.
The presence of host-specific Tc cells in 5 of 6 patients
without GVHD clearly demonstrated that an antihost immune
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response can emerge after transplantation whether GVHD
develops clinically or not. Likewise, in the mouse, splenic Tc
cells with host reactivity have been detected in recipients
without any sign of GVHD after mH antigen-disparate BMT
(28). Clearly, this absence of correlation poses questions as to
the role of classic cytotoxic cells in the process of GVHD. It
might be that the relevance of antihost-specific Tc cells relates
to the tissue distribution of their target antigens. As yet, little
is known about the expression of mH antigens. Recently we
found that several Tc cell-defined mH antigens were differen-
tially expressed on human bone marrow precursor cells and in
the skin (19 and De Bueger MM, et al., manuscript in prepa-
ration). Hence, these observations suggest that some, but not
all, mH antigens might play a role as target antigens in graft
rejection and GVHD.
Another possibility is that, while antihost Tc cells could
become cytotoxic when stimulated in vitro, they may be held
in an "anergic" State in vivo. In this respect our observations
in patients without GVHD may relate to the discordances
described between in vivo and in vitro assays in recent studies
of immunologic tolerance in man as well as in the mouse (20-
22). Although the mechanism of in vivo anergy remains unclear,
the administration of immunosuppressive agents to patients
might play a role. Here it is noteworthy that, while in vitro
cytotoxicity was observed in nearly all cases, patients reeeiving
CsA (n = 5) all developed GVHD—whereas, of those reeeiving
MTX, only 5 of 11 developed GVHD. Whether these fmdings
have a bearing on the capacity of MTX versus CsA to establish
in vivo tolerance, however, cannot be concluded from our
studies. Evidence that graft-host tolerance after human BMT
might be mediated by suppressor cell activity was provided by
Tsoi et al. (23), who showed that the lymphocytes from long-
term survivors without GVHD could speeifieally suppress an
in vitro model of the GVHD reaction, but that lymphocytes
from survivors with chronic GVHD could not.
Finally, it should be stressed that the issue of whether
GVHD-related tissue damage is brought about by classic Tc
cells is still unsettled. Therefore, it is of importance to inves-
tigate other possible risk factors, such as antihost Τ helper cells
(24), autocytotoxic null cells (25), and large granulär lympho-
cytes (26), as well as the effects mediated by cytokines (27).
The possible involvement of antihost Th cells is emphasized in
another study, wherein we show a significant correlation be-
tween these cells and the development of acute GVHD (see the
accompanying article).
Analysis of the relation between the time of onset of GVHD
and the initiation of in vitro antihost Tc cell activity would
provide further insight into the role of Tc cells. Unfortunately,
blood samples preeeeding the diagnosis of GVHD were not
available (Table 1). In some cases we observed a clear lag
15
a b c d θ ι
Time interval alter BMT
FlGURE 1. Kinetics of host-specific Tc cell activity: (A) patients
without GVHD, (B) patients with acute GVHD, (C) patients with
chronic GVHD. Bars represent sequential Tc cell activity (% lysis)
against host lymphoblasts of posttransplantation Τ cell lines (E:T =
40:1) derived from patients 1 to 6 without GVHD (A), from patients 7
to 11 with acute GVHD (B), and from patients 12 to 16 with acute and
subsequently chronic GVHD (C). Intervals after BMT in months are:
a: 0-1.5; b- 1.5-3; c: 3-6; d: 6-9; e: 9-12; f: 12-25 The absence of bars
means that no matenal was available from the interval. No Tc cell
activity against autologous donor Τ cell blasts was detected in any of
the Τ cell eultures (Table 3).
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between the onset of GVHD and antihost Tc cell activity,
whereas in others we found that antihost Tc cell activity could
be present as early as a few days after clinical diagnosis of acute
GVHD. In contrast, Tsoi et al. (14) found that in vitro antihost
cytotoxicity measured against fibroblasts could only be opti-
mally demonstrated between 1 and 2 months after the onset of
GVHD. Furthermore, these authors observed a lower incidence
of antihost cytotoxicity. Therefore, our method, using specifi-
cally in vitro restimulated effector Τ cell lines and lymphoblasts
as target cells, seemed to be more sensitive for the detection of
antihost cytotoxicity. Alternatively, the two methods could be
directed against different antigens. In this study, the levels of
Tc cell activity increased to a maximum between 3 and 6
months after grafting (Fig. 1). Whether this trend reflects an
in vivo strengthening of the antihost response or is related to
the suppressive regimen remains unknown. The sharp increase
in Tc cell activity found in patients 9, 14, and 15, which
coincided with the Interruption of CsA administration, favors
the latter Option—yet patients having high antihost Tc cell
activity in the course of MTX or CsA were also found (e.g.,
12,13, and 16). If the immunosuppression indeed may account
for the Tc cell nonresponsiveness observed in some cases, this
effect is host-specific, since we found normal cytotoxicity
against HLA alloantigens in all patients during prophylaxis.
Our study favors the idea that, more often than expected,
interactions between host mH antigens and Tc cell subsets are
initiated after HLA-identical BMT. Apparently, the generation
of specific antihost Tc cells does not necessarily result in an in
vivo antihost attack, so the role of classic cytotoxic effector
cells in human GVHD is questioned. Immunogenetic studies
with cloned cells specific for single mH antigen specificities
and identification of the "major" minors—i.e., those triggering
an injurious Tc cell subset—will be necessary to settle this
issue.
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